申请人:PFIZER INC.
公开号:EP0220939A1
公开(公告)日:1987-05-06
6-(1-Carbamoyl-1-hydroxymethyl)penicillanic acid derivatives of the formula:
wherein
n is 0, 1 or 2;
R is hydrogen, a radical group forming an ester hydrolyzable under physiological conditions, or an acyloxymethyl or 1-(acyloxy)ethyl radical derived from a conventional beta-lactam antibiotic; and
R1 and R2 are taken separately and are each independently for example, hydrogen, (C1-C4)alkyl, (C5-C6)cycloalkyl, phenyl benzyl or one of said groups substituted by methyl, hydroxy, (Cl-C2)alkoxy, -COOR3, or -CONR3R4; or
R1 and RZ are taken together with the nitrogen to which they are attached to form for example, a pyrrolidine, piperidine, perhydroazepine, morpholine 4-[formyl, (C1-C4)alkyl, phenyl benzyl, pyridyl or 2-hydroxyethyl]piperazine, indoline, isoindoline, 1,2,3,4-tetrahydroquinoline or 1,2,3,4-tetrahydroisoquinoline ring system, or one af said ring systems substituted by methyl, hydroxy, hydroxymethyl, carboxy, carbamoyl, -COOR3 or -CONR3R4.
The compounds are useful as antibacterial agents and/or betalactamase inhibitors.
式中的 6-(1-氨基甲酰基-1-羟甲基)青霉烷酸衍生物:
其中
n 是 0、1 或 2;
R 是氢、在生理条件下可水解的形成酯的基团、或来自传统 beta-内酰胺类抗生素的酰氧基甲基或 1-(酰氧基)乙基;以及
R1 和 R2 分别独立地为氢、(C1-C4)烷基、(C5-C6)环烷基、苯基苄基或被甲基、羟基、(Cl-C2)烷氧基、-COOR3 或-CONR3R4 取代的上述基团之一;或
R1 和 RZ 与它们所连接的氮一起形成例如吡咯烷、哌啶、过氢氮杂卓、吗啉 4-[甲酰基、(C1-C4)烷基、苯基苄基、吡啶基或 2-羟乙基]哌嗪、吲哚啉、异吲哚啉、1,2,3,4-四氢喹啉或 1,2,3,4-四氢异喹啉环系,或其中一个被甲基、羟基、羟甲基、羧基、氨基甲酰基、-COOR3 或 -CONR3R4 取代的环系。
这些化合物可用作抗菌剂和/或β-内酰胺酶抑制剂。